Loading...
Loading...
Arena Pharmaceuticals, Inc.
ARNA and Eisai Inc. announced today the
expansion of the lorcaserin marketing and supply agreement between Arena
Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH,
and Eisai Inc. Lorcaserin is an investigational drug candidate intended for
weight management. In addition to the United States, the territories in the
expanded agreement now include most of North and South America, including
Canada, Mexico and Brazil. This expansion builds on the agreement executed by
Eisai and Arena in July 2010 for Eisai's exclusive rights to market and
distribute lorcaserin in the United States, subject to lorcaserin's approval
by the US Food and Drug Administration (FDA).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in